The Ceiling of Psychedelic Medicine: Why Scale, Not Science, Is the Real Challenge
Stephanie Karzon Abrams, Clinical Pharmacology, Founder of Beyond Consulting
For a long time, the question surrounding psychedelics was simple: do they work?
Today, that question is dissolving. With late-stage clinical trials demonstrating efficacy in treatment-resistant depression, the conversation has changed quite a bit. The science, while still evolving, is no longer the primary barrier and the real question now is far more complex, and far less discussed: Can these treatments actually scale?
In traditional psychiatry, a drug is a product. It is prescribed, dispensed, and taken often daily, often independently. Psychedelic therapies invert this model, as they are more than pharmacological interventions. Psychedelic therapies are experiential treatments, embedded within time, environment, and human support. This means we are dealing with an entire model, and the molecule is only one part of the equation. The rest is delivered through therapists, environment, protocols, and presence. Psychedelics are drugs, yes, but they are enveloped in services. And these services do not scale the way pills do.
The Geometry of a Session
Consider the structure of a single psilocybin-assisted therapy session:
6–8 hours of continuous care (perhaps we can shorten to 4 hours with Cybin)
2 trained clinicians present
A dedicated, controlled environment
Preparation and integration sessions before and after
Clinical oversight and compliance (admin, consultation and monitoring notes)
FULL. DAY. IMMERSION.
From an operational perspective, each treatment room becomes occupied like a private suite. One patient enters in the morning and leaves in the late afternoon. There is no stacking, no overlap, no compression of time…unless you have double the staff and multiple rooms. And no matter how strong the clinical outcomes are, this geometry does not bend easily.
The Human Bottleneck
If time is the first constraint, people are the second. Each session requires trained professionals who are not only clinically competent, but specifically trained in holding psychedelic space. This is not a skill set that can be rapidly scaled or automated. Training takes time and training does not often suffice. Experience makes all the difference, and that also takes time— more time than the training. And unlike other areas of medicine, where efficiency often increases with standardization, psychedelic care resists full mechanization. The therapeutic relationship remains central because presence cannot be outsourced.
We can build clinics quickly, but the experienced clinicians will not be created at the same speed.
Safety is The Structure and The Ceiling
Layered on top of this is a regulatory reality where psychedelic treatments, particularly Spravato (Esketamine by Johnson & Johnson), and the anticipated Comp360 psilocybin will continue to launch within tightly controlled frameworks. These include certified sites, trained providers, in-clinic administration, monitoring requirements, and restricted distribution.
Ok ,to be expected, but they also introduce a lot of friction. Each additional layer of these safety measures adds time, cost, and operational complexity, and yes, you guessed it, they’ll define the upper limit of scalability.
When you combine time, staffing, and infrastructure, there’s no denying that the economic profile is resource-intensive.
Higher per-session costs in turn create pressure on reimbursement models and payer adoption. The paradox emerges: The treatments are powerful, but the system required to deliver them is expensive and slow.
A well-run clinic with multiple rooms may treat a few dozen patients per week. A network of clinics may reach thousands per year. But the populations in need reach numbers in the millions, and even under optimistic scaling scenarios, access remains limited because the system just cannot deliver enough experiences, safely and fast enough.
Competing Visions of the Future
One approach is to preserve the depth of the experience and build infrastructure around it. This path prioritizes fidelity, safety, and the full therapeutic arc, but treats fewer people. Another approach is to modify the experience itself—shortening duration, increasing predictability, and designing molecules that better fit into clinical workflows (eg Cybin’s molecule, predicted to last half the time). Both strategies are attempts to answer the same question: How do we expand capacity without losing what makes these treatments effective?
Perhaps it’s more of a philosophical challenge than an operational one. Psychedelic therapies derive much of their power from time, depth, emotional intensity, experiential resonance, and the therapeutic relationship. Since none of these are easily compressed into variables, do we optimize for scale and potentially dilute the experience in doing so? Or do we limit access and preserve the experience.
Uh-Oh. Are those really our two best options?
A New Category of Care Emerges, and The Reality Settles In
The first mistake is trying to fit psychedelic therapies into existing categories. We know that they are not daily medications, nor are they brief interventions. They may be better understood as high-impact, low-frequency treatments, more akin to a “procedure” (of the soul), or intensive specialty care than primary psychiatry. If we think of them in this way, our expectations around them change, and we come to terms that within the medical, FDA-approved model, not everyone will receive them immediately, and not every clinic will offer them. The impact can and will be profound, but our healthcare system will have to transform sufficiently to achieve it.
One thing is certain if your center operates in a clinical or medical setting, long-term sustainability will depend on offering insurance-eligible services — unless you are exclusively serving a high-net-worth clientele through premium, concierge, or specialty care.
Cash-pay offerings don't need to disappear (eg IM/IV KAT), but integrating Spravato, TMS, FDA-approved psilocybin formulations, and insurance-accepted medical consultations into your model is what will allow your practice not just to survive, but to grow.
At Beyond, we've spent years gathering the experience — clinical, operational, and regulatory — that this moment requires, and we're ready to pass it on. If you're exploring integrating, KAP, Spravato, COMP360 or psilocybin readiness, we'd love to hear from you.
Visit the Comp360 Readiness & Psilocybin Hub
Visit our page for all things Psychedelic Assisted Therapy and Integrative Health
